-
Mashup Score: 0The Multiple Myeloma Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 2Myeloma Sessions: Novel targets in 2022 | VJHemOnc - 2 year(s) ago
Faith Davies:Thank you for joining us. We’re currently at Myeloma 2022, and it’s a real pleasure for me to introduce two of my colleagues. We have Charlotte Pawlyn, who is from the Institute of cancer research in the Royal Marsden hospital in London. And we have Hearn Cho, who is from the Mount Sinai hospital in New York, and is also the chief medical officer for the MMRF. And as you can see, two…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSessions | Want to hear more about novel targets in myeloma? Join @FaithEDavies1, @HJChoMDPhD1 & @_DrCP as they discuss IMiD resistance, novel treatments for amyloidosis, and more. 👉https://t.co/M9dFEWkyEk👈 #MMsm #HemOnc #Myeloma #ImmunoOnc #Myeloma22 https://t.co/0EG1rxdckX
-
-
Mashup Score: 1Myeloma Sessions: Day 2 highlights from Myeloma 2022 | VJHemOnc - 2 year(s) ago
Irene Ghobrial:My name is Irene Ghobrial. I’m from the Dana-Farber Cancer Institute in Boston, Massachusetts.Sigurdur Kristinsson:My name is Sigurdur Kristinsson. I’m from the University of Iceland. So the iStopMM study is called Iceland screens and treats and prevents myeloma. So basically we wanted to ask, “Should we screen for MGUS? Does that lead to an improvement in overall survival? So…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #VJSessions | @DrGarethMorgan1, @Rfonsi1, @Leif_Bergsagel & @akeithstewart discuss the biology behind BCL2 inhibitors, resistance to immunotherapies, and more at #Myeloma22. Watch now: 👉https://t.co/HZHAFkRIv3👈 #MMsm https://t.co/vQHBofBXbO
-
-
Mashup Score: 0
Hermann Einsele:Hello, everybody. My name is Hermann Einsele. I am based in Würzburg in Germany, and it’s my great pleasure to report from the Myeloma 2022 in Scottsdale. And it’s a great pleasure for me for the discussion to have two real experts with me on T-cell engaging therapies in myeloma, Professor Nina Shah and Professor Tom Martin from California. And the topic of our discussion today…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #VJSessions | Join @ninashah33, @TomBmt133 and @H_Einsele as they have a fascinating roundtable discussion on the current status of T-cell engager therapy in multiple myeloma. Watch here: 👉https://t.co/CPSuG5dI0c👈 #Myeloma22 #MMsm #MultipleMyeloma #HemOnc #ImmunoOnc https://t.co/JbzrBUgNzu
-
-
Mashup Score: 0
Lawrence Boise:Hello, I’m Lawrence Boise from the Winship Cancer Institute at Emory University. And along with my co-chair, Dr Paola Neri from the University of Calgary. We are at the Myeloma 2022 in Scottsdale, Arizona. And we just finished up with a really exciting session on novel targets in myeloma.Lawrence Boise:Paula, when… I love novel target sessions, because there’s a lot of variety…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #VJSessions | Leading experts Paola Neri (@UCalgary) and Lawrence Boise (@WinshipAtEmory) discuss PIKfyve, resistance to PIs and IMiDs, PROTAC therapy, and more at #Myeloma22. Watch here: 👉https://t.co/nypPt3WvMN👈 #MMsm #MultipleMyeloma https://t.co/Nc6JaZrI9Y
-
-
Mashup Score: 8MDS Sessions: The impact of AI in MDS | VJHemOnc - 2 year(s) ago
A session with experts Amer Zeidan, Aziz Nazha, and Anne Sophie Kubasch, who discuss the impact of artificial intelligence and machine learning in MDS.
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #VJSessions | Join leading experts @Dr_AmerZeidan, @AzizNazhaMD & @ASKubasch as they hold a fascinating discussion on the impact of artificial intelligence & machine learning in MDS. Watch now: 👉https://t.co/9Ggy0hVUEI👈 #MDSsm #MyelodysplasticSyndromes https://t.co/ajQplcj9F8
-
-
Mashup Score: 0Myeloma Sessions: Genomics in the age of I-O | VJHemOnc - 2 year(s) ago
Gareth Morgan:Hello, my name is Gareth Morgan. I’m here in Scottsdale, Arizona at the Myeloma 2022 meeting. I’m with two good colleagues, Leo Rasche, and Francesco Maura. We’ve just been in the genomics session. I’d just like to ask you, Leo, what did you think of the session and what did you think the take home message was?Leo Rasche:Oh, the session was great. But it’s difficult to have a good…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSessions | Join leading experts @FrancescoMaura4, @DrGarethMorgan1 & Leo Rasche as they discuss genomics in myeloma, highlighting questions raised by immunotherapy, changing risk stratification & more: 🎥: https://t.co/rLSswyjRtK #MMsm #HemOnc #Myeloma #ImmunoOnc #Myeloma22 https://t.co/MMJf6J4rnK
-
-
Mashup Score: 5The Multiple Myeloma Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/lJWPVtOuu8 Thanks to @VJHemOnc @MatthewHoMD @agarwalonc #mmsm #vjsessions
-
RT @Myeloma_Doc: The latest The Multiple Myeloma Daily! https://t.co/lJWPVtOuu8 Thanks to @VJHemOnc @MatthewHoMD @agarwalonc #mmsm #vjsessi…
-
-
Mashup Score: 1
Lawrence Boise:Hello, I’m Lawrence Boise from the Winship Cancer Institute at Emory University. And along with my co-chair, Dr Paola Neri from the University of Calgary. We are at the Myeloma 2022 in Scottsdale, Arizona. And we just finished up with a really exciting session on novel targets in myeloma.Lawrence Boise:Paula, when… I love novel target sessions, because there’s a lot of variety…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 #VJSessions | Join leading experts Paola Neri (@UCalgary) and Lawrence Boise (@WinshipAtEmory) as they bring you the latest updates in novel targets for the treatment of multiple myeloma. Watch here: 👉https://t.co/3wwJc8EG9H👈 #MMsm #Myeloma22 #HemOnc #ImmunoOnc https://t.co/SqOWCPxcT8
-
-
Mashup Score: 1Myeloma Sessions: Day 2 highlights from Myeloma 2022 | VJHemOnc - 2 year(s) ago
Irene Ghobrial:My name is Irene Ghobrial. I’m from the Dana-Farber Cancer Institute in Boston, Massachusetts.Sigurdur Kristinsson:My name is Sigurdur Kristinsson. I’m from the University of Iceland. So the iStopMM study is called Iceland screens and treats and prevents myeloma. So basically we wanted to ask, “Should we screen for MGUS? Does that lead to an improvement in overall survival? So…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#VJSessions | At #Myeloma22, leading experts got together to cover the latest updates in myeloma treatment & management. Join @DrGarethMorgan1, @Rfonsi1, @Leif_Bergsagel & @akeithstewart as they discuss highlights from this year's meeting: 👉https://t.co/5e4opueDyk👈 #MMsm https://t.co/Ch2DiwwFye
-
The latest The Multiple Myeloma Daily! https://t.co/HDrP46iLDh Thanks to @TargetedOnc @IMFjimMYELOMA @VJHemOnc #mmsm #vjsessions